Sanofi Names Garijo CEO, Signaling Execution-First Era

Sanofi's appointment of Belén Garijo as Chief Executive Officer, effective May 1, 2026, places a physician-trained executive with direct operational experience in GMP-intensive environments at the helm of one of the world's largest biopharma manufacturers. For plant heads and QA directors, the Board's explicit mandate around execution discipline and science-to-performance translation signals that manufacturing quality systems and capital allocation decisions will face heightened scrutiny in the near term.

Garijo's appointment was ratified at Sanofi's Mixed General Meeting of Shareholders on April 29, 2026, under Board Chairman Frédéric Oudéa. The Board's decision to appoint her was originally made on February 11, 2026. Oudéa framed the mandate clearly: strengthen execution discipline, refine capital allocation, and more consistently translate scientific quality into sustainable performance. For regulatory affairs leads, that language maps directly onto process validation rigor and lifecycle management under frameworks such as ICH Q10.

Garijo brings a track record that is directly relevant to large-scale pharmaceutical operations. As CEO and President of Merck for five years, she led a transformation of its Healthcare business that included portfolio repositioning and R&D reorganization. Earlier in her career, as Senior Vice President of Global Operations Europe at Sanofi-Aventis, she led the integration of Genzyme following its acquisition, a post-merger manufacturing harmonization challenge with significant GMP and sterility assurance implications. She began her career as a practicing physician specializing in clinical pharmacology at La Paz Hospital in Madrid.

The General Meeting also approved the appointment of Christel Heydemann, CEO of Orange, as an independent board member, cited for her expertise in digital and AI technologies. The Board now comprises 16 members, with an independence rate of 79%, 57% women, and 8 members of foreign nationality. The annual dividend for fiscal year 2025 was set at 4.12 euros per share, payable May 7, 2026. Board mandates for Christophe Babule and Jean-Paul Kress were renewed.